News | March 14, 2024
Zydus launches generic version of Olaparib ‘IBYRA’ in India
The drug will target specific genetic mutations prevalent in certain types of cancers
The drug will target specific genetic mutations prevalent in certain types of cancers
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
One in two women with advanced ovarian cancer has an HRD-positive tumor
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)